Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 3:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Influenza A Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59

NCT06560151
View directory record Official record
Conditions
Influenza
Interventions
3.75 µg H5N8 antigen plus full dose AS03A, 7.5 µg H5N8 antigen plus full dose AS03A, 15 µg H5N8 antigen plus full dose AS03A, 3.75 µg H5N8 antigen plus half dose AS03A, 7.5 µg H5N8 antigen plus half dose AS03A, 15 µg H5N8 antigen plus half dose AS03A, 3.75 µg H5N8 antigen plus MF59, 7.5 µg H5N8 antigen plus MF59, 15 µg H5N8 antigen plus MF59, 3.75 µg H5N1 antigen plus full dose AS03A, 7.5 µg H5N1 antigen plus full dose AS03A, 15 µg H5N1 antigen plus full dose AS03A, 3.75 µg H5N1 antigen plus MF59, 7.5 µg H5N1 antigen plus MF59, 15 µg H5N1 antigen plus MF59
Biological
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years and older
Enrollment
1,380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
20
States / cities
Atlanta, Georgia • Savannah, Georgia • Oak Lawn, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 27, 2026, 3:33 PM EDT
Completed Phase 1 Interventional

Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally

NCT00489931
View directory record Official record
Conditions
Influenza A Virus, H5N1 Subtype, Influenza A Virus, Influenzavirus A, Orthomyxovirdae, H5N1 Virus
Interventions
VRC-AVIDNA036-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 27, 2026, 3:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

NCT00743275
View directory record Official record
Conditions
Influenza
Interventions
Split, Inactivated, Trivalent Influenza vaccine (Fluzone®)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Sep 27, 2026, 3:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza

NCT03682120
View directory record Official record
Conditions
Avian Influenza, Influenza Immunisation
Interventions
A/H7N9, MF59, Phosphate Buffered Saline (PBS) diluent
Biological · Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
372 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • St Louis, Missouri • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Sep 27, 2026, 3:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults

NCT05755620
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Quadrivalent Inactivated Vaccine, Sodium Chloride, 0.9%, VRC-FLUNPF099-00-VP (H1ssF_3928)
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 27, 2026, 3:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

How Does the Clinical Tool 'What's Going Around' Affect Clinical Practice

NCT01979588
View directory record Official record
Conditions
Influenza Like Illness, Asthma, Group A Streptococcal Infection, Pertussis
Interventions
What's Going Around tool, Control
Other
Lead sponsor
Endeavor Health
Other
Eligibility
Not listed
Enrollment
206,703 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Sep 27, 2026, 3:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Almonds on Immune Strength and Response to Flu Vaccination in Overweight Older Men and Postmenopausal Women: A Randomized Controlled Study

NCT05031663
View directory record Official record
Conditions
Immune Response, Inflammation
Interventions
Almond group, Control Group
Dietary Supplement
Lead sponsor
Loma Linda University
Other
Eligibility
40 Years to 70 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 27, 2026, 3:33 PM EDT
Completed No phase listed Observational

Clinical Characteristics and Outcomes in Patients Diagnosed With Novel Influenza A (H1N1)

NCT01024673
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2021 · Synced Sep 27, 2026, 3:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults

NCT01995695
View directory record Official record
Conditions
Influenza A Virus, H7N9 Subtype
Interventions
Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine, Inactivated subvirion H7N9 influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Sep 27, 2026, 3:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults

NCT05397119
View directory record Official record
Conditions
Influenza, Pandemic
Interventions
BW-1014: 25 µg rH5 in 20% NE - pipette - IN, BW-1014: 50 µg rH5 in 20% NE - pipette - IN, BW-1014: 100 µg rH5 in 20% NE - pipette - IN, rH5 (100 µg) control - pipette - IN, Saline (Placebo) - pipette - IN, H5N1 IIV - IM
Biological
Lead sponsor
BlueWillow Biologics
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 27, 2026, 3:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel

NCT05163730
View directory record Official record
Conditions
COVID-19, Influenza A, Influenza Type B
Interventions
COVID-19/ Flu A&B Rapid Panel
Device
Lead sponsor
Abbott Rapid Diagnostics Jena GmbH
Industry
Eligibility
Not listed
Enrollment
2,472 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Easley, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Sep 27, 2026, 3:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Determine a Preference for Fluzone Vaccine Given Intradermally (ID) and Intramuscularly (IM) in Healthy Adults

NCT00623181
View directory record Official record
Conditions
Influenza
Interventions
Fluzone: Influenza virus vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 49 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
2
States / cities
Grove City, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 27, 2026, 3:33 PM EDT
Not listed Not applicable Interventional

Assessment of the Clinical Performance of the ARROW-FLU System

NCT02996136
View directory record Official record
Conditions
Influenza, Human
Interventions
Flu Symptoms
Device
Lead sponsor
Sekisui Diagnostics, LLC
Industry
Eligibility
Not listed
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
14
States / cities
Little Rock, Arkansas • Coral Gables, Florida • Lauderdale Lakes, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2016 · Synced Sep 27, 2026, 3:33 PM EDT
Completed Phase 3 Interventional

Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316

NCT02026349
View directory record Official record
Conditions
Influenza
Interventions
favipiravir, Placebo
Drug
Lead sponsor
MDVI, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
60
States / cities
Birmingham, Alabama • Hunstville, Alabama • Hot Springs, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Sep 27, 2026, 3:33 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection

NCT03376321
View directory record Official record
Conditions
Influenza A
Interventions
Pimodivir 600 mg, Placebo, SOC Treatment
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
13 Years to 85 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
28
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Fresno, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 27, 2026, 3:33 PM EDT
Completed Phase 1 Interventional

Testing the AVI-7100 Flu Drug in Healthy Volunteers

NCT01747148
View directory record Official record
Conditions
Influenza
Interventions
AVI-7100 versus placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 25, 2017 · Synced Sep 27, 2026, 3:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Three Licensed Influenza Vaccines

NCT03068949
View directory record Official record
Conditions
Influenza
Interventions
FluBlok, Fluzone, FluCelVax, Fluzone HD
Biological
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 49 Years
Enrollment
413 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Sep 27, 2026, 3:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older Adults

NCT01014806
View directory record Official record
Conditions
Influenza
Interventions
Influenza VLP Vaccine, TIV
Biological
Lead sponsor
Novavax
Industry
Eligibility
60 Years and older
Enrollment
467 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
6
States / cities
Pembroke Pines, Florida • Rochester, Minnesota • Providence, Rhode Island + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Sep 27, 2026, 3:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Eldery High Dose TIV 2005

NCT00115531
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years and older
Enrollment
414 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
5
States / cities
Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Sep 27, 2026, 3:33 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects

NCT01162122
View directory record Official record
Conditions
Influenza
Interventions
MF59 adjuvanted trivalent subunit influenza vaccine (aTIV), Non-adjuvanted trivalent subunit influenza vaccine (TIV)
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
65 Years and older
Enrollment
7,109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
21
States / cities
Phoenix, Arizona • DeLand, Florida • Jacksonville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Sep 27, 2026, 3:33 PM EDT
Completed Not applicable Interventional Results available

Safe Administration of Flu Vaccine to Egg Allergic Children

NCT01264601
View directory record Official record
Conditions
Egg Allergy
Interventions
Trivalent Influenza Vaccine
Biological
Lead sponsor
University of Michigan
Other
Eligibility
6 Months to 24 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
San Diego, California • Ann Arbor, Michigan • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Sep 27, 2026, 3:33 PM EDT
Completed Phase 2 Interventional Results available

Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza

NCT01068912
View directory record Official record
Conditions
Influenza
Interventions
Favipiravir, Placebo comparator
Drug
Lead sponsor
MDVI, LLC
Industry
Eligibility
20 Years to 80 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
148
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 118 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Sep 27, 2026, 3:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Safety and Immunogenicity of VAX128A, VAC128B and VAX128C Novel H1N1 Influenza Vaccine in Healthy Adults

NCT01172054
View directory record Official record
Conditions
Influenza
Interventions
VAX128, Placebo
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Miami, Florida • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Sep 27, 2026, 3:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Pilot Study for Collection of Anti-Influenza A Immune Plasma

NCT00984451
View directory record Official record
Conditions
Influenza A Virus Infection, Swine Flu
Interventions
Plasma collection following infection or vaccination with influenza A
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years · Male only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2019 · Synced Sep 27, 2026, 3:33 PM EDT